Andrew Bevan

MRes, MRSB, CBiol, Executive Director, Business Optimization Lead, Interventional Studies

Andrew has worked in the CRO industry for over 20 years, 13 of which have been with PPD managing large international Phase III – IV cardiovascular and metabolic studies, as well as studies in pediatric and rare disease populations. He has held the position of project director for 6 years, with oversight responsibility for large peri- and post-approval interventional and non-interventional studies, delivering strong strategic leadership, cross-functional management, and a rigorous approach to risk management. As therapeutic area lead for cardiovascular, metabolic and renal, Andy leads a team of directors, associate directors, and project managers responsible for project delivery, provides therapeutic specific operations consulting services to internal and external customers, and drives the short and long-range corporate strategies within the therapeutic area through via close partnership with internal therapeutic and business experts.